Six at six: Interleukin-6 measured 6 H after the initiation of sepsis predicts mortality over 3 days

Shock

Volumn 17, Issue 6, 2002, Pages 463-467

  Remick, Daniel G ^a,d   Bolgos, Gerald R ^a   Siddiqui, Javed ^a   Shin, Jungsoon ^c   Nemzek, Jean A ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c FLORIDA STATE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Cytokines; Inflammation; Lymphocytes; Neutrophils; Organ injury

Indexed keywords

AUTACOID; INTERLEUKIN 6;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; BLOOD CELL COUNT; CECUM; FEMALE; HUMAN; IMMUNOLOGY; INJURY; LIGATION; METABOLISM; MOUSE; NEUTROPHIL; PERITONITIS; PUNCTURE; SEPSIS; TIME;

ANIMALS; BLOOD CELL COUNT; CECUM; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LIGATION; MICE; MICE, INBRED BALB C; NEUTROPHILS; PERITONITIS; PUNCTURES; SEPSIS; TIME FACTORS;

EID: 0036595292     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200206000-00004     Document Type: Article

References (34)

1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Heiterbrand JD, Ely EW, Fisher CJ, Jr., and Recombinant human protein CWEiSSsg: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
2. Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 25:556-566, 1999.
3. Abraham E, Marshall JC: Sepsis and mediator-directed therapy: rethinking the target populations. Mediator-directed therapy in sepsis: Rethinking the target populations. Toronto, Canada, 31 October-1 November 1998. Mol Med Today 5:56-58, 1999.
4. Kox WJ, Volk T, Kox SN, Volk HD: Immunomodulatory therapies in sepsis. Intensive Care Med 26:5124-8128, 2000.
5. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van ScR, Eerenberg-Belmer AJ, Thijs LG, Aarden LA: Increased plasma levels of interleukin-6 in sepsis [see comments]. Blood 74:1704-1710, 1989.
6. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169:333-338, 1989.
7. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D: Immunopathologic alterations in murine models of sepsis of increasing severity. Infection Immunity 67:6603-6610, 1999.
8. Ebong SJ, Call DR, Bolgos G, Newcomb DE, Granger JI, O'Reilly M, Remick DG: Immunopathologic responses to non-lethal sepsis. Shock 12:118-126, 1999.
9. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL: Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infection Immunity 64:4733-4738, 1996.
10. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res 29:189-201, 1980.
11. Remick DG, Newcomb DE, Bolgos GL, Call DR: Comparison of the mortality and inflammatory response of two models of sepsis: Lipopolysaccharide vs. cecal ligation and puncture. Shock 13:110-116, 2000.
12. Ebong SJ, Goyert SM, Nemzek JA, Kim J, Bolgos GL, Remick DG: Critical role of CD14 for production of proinflammatory cytokines and cytokine inhibitors during sepsis with failure to alter morbidity or mortality. Infection Immunity 69:2099-2106, 2001.
13. Call DR, Nemzek JA, Ebong SJ, Bolgos GL, Newcomb DE, Remick DG: Ratio of local to systemic chemokine concentrations regulates neutrophil recruitment. Am J Pathol 158:715-721, 2001.
14. Lundblad R, Sandven P, Giercksky KE: The physical nature of a large bowel perforation predicts severity of the subsequent inflammatory response. Shock 3:455-461, 1995.
15. Villa P, Shaklee CL, Meazza C, Agnello D, Ghezzi P, Senaldi G: Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of a murine model of polymicrobial peritonitis and sepsis. J Infect Dis 178:471-477, 1998.
16. Ertel W, Morrison MH, Wang P, Ba ZF, Ayala A, Chaudry IH: The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann Surg 214:141-148, 1991.
17. Salkowski CA, Detore G, Franks A, Falk MC, Vogel SN: Pulmonary and hepatic gene expression following cecal ligation and puncture: Monophosphoryl lipid A prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration. Infection Immunity 66:3569-3578, 1998.
18. Chaudry IH, Tabata Y, Schleck S, Baue AE: Effect of splenectomy on reticuloendothelial function and survival following sepsis, J Trauma 20:649-656, 1980.
19. Baker CC. Chaudry IH, Gaines HO, Baue AE: Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331-335, 1983.
20. Barke RA, Birklid S, Chapin RB, Roy S, Brady PS, Brady LJ: The effect of surgical treatment following peritoneal sepsis on hepatic gene expression. J Surg Res 60:101-106, 1996.
21. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine [see comments]. Chest 101:1644-1655, 1992.
22. Oberhoffer M, Vogelsang H, Russwurm S, Hartung T , Reinhart K: Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 37:363-368, 1999.
23. Simpson AJ, Smith MD, Weverling GJ, Suputtamongkol Y, Angus BJ, Chaowagul W, White NJ, van Deventer SJ, Prins JM: Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J Infect Dis 181:621-625, 2000.
24. Terregino CA, Lopez BL, Karras DJ, Killian AJ, Arnold GK: Endogenous mediators in emergency department patients with presumed sepsis: are levels associated with progression to severe sepsis and death? [see comments]. Ann Emerg Med 35:26-34, 2000.
25. Reinhart K, Wiegand-Lohnert C. Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study [see comments] [published erratum appears in Crit Care Med 1996 Sep;24(9):1608]. Crit Care Med 24:733-742, 1996.
26. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S and Kurokawa A: Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 27:1262-1264, 1999.
27. Libert C, Vink A, Coulie P, Brouckaert P, Everaerdt B, Van Snick J, Fiers W: Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. Eur J Immunol 22:2625-2630, 1992.
28. Leon LR, White AA, Kluger MJ: Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol 275:R269-R277, 1998.
29. Gennari R, Alexander JW: Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defense. Crit Care Med 23:1945-1953, 1995.
30. Rollwagen FM, Li YY, Pacheco ND, Dick EJ, Kang YH: Microvascular effects of oral interleukin-6 on ischemia/reperfusion in the murine small intestine. Am J Pathol 156:1177-1182, 2000.
31. Mancuso G, Tomasello F, Migliardo M, Delfino D, Cochran J, Cook JA, Teti G: Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infection Immunity 62:4997-5002, 1994.
32. Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R: Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infection Immunity 64:3231-3235, 1996.
33. Endo S, Inada K, Yamada Y, Wakabayashi G, Ishikura H, Tanaka T, Sato S: Interleukin 18 (IL-18) levels in patients with sepsis. J Med 31:15-20, 2000.
34. Remick DG, Call DR, Ebong SJ, Newcomb DE, Nybom P, Nemzek JA, Bolgos GE: Combinantion immuntherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit Care Med 29:473-481, 2001.